Search Result

Results for "

histone methyltransferase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA Methyltransferase (3) HDAC (4) Histone Demethylase (3) Histone Methyltransferase (71) Aldehyde Dehydrogenase (ALDH) (1) Antibiotic (1) Apoptosis (15) Autophagy (5) Bacterial (1) Chemerin Receptor (1) Cholinesterase (ChE) (1) Epigenetic Reader Domain (1) GCGR (1) Influenza Virus (2) Interleukin Related (1) Keap1-Nrf2 (1) NF-κB (1) Orthopoxvirus (3) Parasite (1) SARS-CoV (1) Sirtuin (1) TNF Receptor (1) VSV (2) WDR5 (1)
By Research Areas:	Cancer (75) Cardiovascular Disease (1) Infection (8) Inflammation/Immunology (3) Neurological Disease (2)

By Targets:

DNA Methyltransferase (3)

HDAC (4)

Histone Demethylase (3)

Histone Methyltransferase (71)

Aldehyde Dehydrogenase (ALDH) (1)

Antibiotic (1)

Apoptosis (15)

Autophagy (5)

Bacterial (1)

Chemerin Receptor (1)

Cholinesterase (ChE) (1)

Epigenetic Reader Domain (1)

GCGR (1)

Influenza Virus (2)

Interleukin Related (1)

Keap1-Nrf2 (1)

NF-κB (1)

Orthopoxvirus (3)

Parasite (1)

SARS-CoV (1)

Sirtuin (1)

TNF Receptor (1)

VSV (2)

WDR5 (1)

By Research Areas:

Cancer (75)

Cardiovascular Disease (1)

Infection (8)

Inflammation/Immunology (3)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Histone Methyltransferase Histone Demethylase Histone Acetyltransferase DNA Methyltransferase HDAC COMT ICMT METTL3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136328

EZM0414 TFA 4 Publications Verification SETD2-IN-1 TFA	Histone Methyltransferase	Cancer
EZM0414 TFA is a potent, selective and orally active inhibitor of SETD2 which is a human histone methyltransferase. EZM0414 TFA has anti-proliferative effects .

HY-141430

AS-85	Histone Methyltransferase	Cancer
AS-85 is a potent ASH1L histone methyltransferase inhibitor (IC₅₀=0.6 µM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the K_d value of 0.78 µM .

HY-121093

DC-S239	Histone Methyltransferase	Cancer
DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC₅₀ value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity .

HY-141429A

AS-99 TFA 1 Publications Verification	Histone Methyltransferase Apoptosis	Cancer
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-44062

G9a-IN-1	Histone Methyltransferase	Inflammation/Immunology Cancer
G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer .

HY-10587A

BIX-01294 hydrochloride hydrate	Histone Methyltransferase Apoptosis Autophagy	Cancer
BIX-01294 hydrochloride hydrate is a histone-lysine methyltransferase (HMTase) inhibitor, which selective inhibits the G9aHMTase with IC₅₀ of 1.7 μM, reduces histone-3 lysine (9) methylation (H3K9me), induces autophagy and apoptosis in human glioma cells .

HY-154854

BBDDL2059	Histone Methyltransferase	Cancer
BBDDL2059 is a selective covalent inhibitor of histone methyltransferase EZH2 with an IC₅₀ of 1.5 nM for EZH2-Y641F. BBDDL2059 inhibits lymphoma cell growth at nanomolar concentrations and can be used for anticancer research .

HY-141429

AS-99 free base	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-141429C

AS-99	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-110093

UNC0638 hydrate	VSV Histone Methyltransferase Autophagy Influenza Virus	Infection Cancer
UNC0638 hydrate selectively inhibits G9a and GLP histone methyltransferases with IC₅₀ of 15 nM and 19 nM, respectively. UNC0638 hydrate inhibits TNBC cell invasion and migration in vitro. UNC0638 hydrate is also an inhibitor of EHMT1/2 and induces fetal hemoglobin (HbF) expression in human erythroid progenitor cell culture. In addition, UNC0638 hydrate has anti-FMDV (foot-and-mouth disease virus) and anti-VSV (vesicular stomatitis virus) activities, with excellent potency and selectivity against multiple epigenetic and non-epigenetic targets .

HY-12991A

BIX-01338 hydrate	Histone Methyltransferase	Cancer
BIX-01338 hydrate is a **histone lysine methyltransferase** inhibitor.

HY-15593

Pinometostat 20+ Cited Publications EPZ-5676	Histone Methyltransferase	Cancer
Pinometostat (EPZ-5676) is a potent DOT1L histone methyltransferase inhibitor with a K_i of 80 pM.

HY-121493

TM2-115	Histone Methyltransferase Parasite	Infection
TM2-115 inhibits malaria parasite histone methyltransferases, resulting in rapid and irreversible parasite death .

HY-122182

OTS193320	Histone Methyltransferase Apoptosis	Cancer
OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (DOX; HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .

HY-114209

MRK-740	Histone Methyltransferase	Cancer
MRK-740 is a potent, selective and substrate-competitive PRDM9 histone methyltransferase inhibitor with an IC₅₀ of 80 nM. MRK-740 is more selective for PRDM9 than other histone methyltransferases and other non-epigenetic targets. MRK-740 reduces PRDM9-dependent trimethylation of H3K4 (IC₅₀ = 0.8 µM) .

HY-112445

SGC3027 3 Publications Verification	Histone Methyltransferase	Cancer
SGC3027 is a **histone methyltransferase inhibitor . SGC3027 is the first potent, selective and cell active chemical probe for PRMT7** .

HY-142093

NSD3-IN-1	Histone Methyltransferase	Cancer
NSD3-IN-1 (compound B1) is an inhibitor of histone methyltransferase NSD3 with an IC₅₀ value of 28.58 μM .

HY-100757

CPUY074020	Histone Methyltransferase	Cancer
CPUY074020 is a potent and oral bioavailable inhibitor of histone methyltransferase G9a, with an IC₅₀ of 2.18 μM. CPUY074020 possesses anti-proliferative activity .

HY-111390

Dot1L-IN-2	Histone Methyltransferase	Cancer
Dot1L-IN-2 is a potent, selective and orally bioavailable inhibitor of Dot1L (a **histone methyltransferase), with an IC₅₀ and K_i** of 0.4 nM and 0.08 nM, respectively.

HY-145813

MU1656	Histone Methyltransferase	Cancer
MU1656 is a potent and selective inhibitor of histone methyltransferase DOT1L, with an IC₅₀ of 2 nM. MU1656 can be used for the research of hematological malignancies .

HY-A0298

EZH2-IN-2	Histone Methyltransferase	Cancer
EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC₅₀ of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity .

HY-122936

Tanshindiol C	Histone Methyltransferase Keap1-Nrf2 Sirtuin	Cardiovascular Disease Cancer
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone *Methyltransferase) inhibitor with an IC₅₀* of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research .

HY-148458

EZH2-IN-14	Histone Methyltransferase	Cancer
EZH2-IN-14 is a selective EZH2 (Histone *Methyltransferase) inhibitor with an IC₅₀* of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1 .

HY-N2019

Chaetocin 5+ Cited Publications	Histone Methyltransferase Bacterial Antibiotic	Infection Cancer
Chaetocin is a specific inhibitor of the histone methyltransferase (HMT) SU(VAR)3-9 with an IC₅₀ of 0.6 μM for SU(VAR)3-9. It also inhibits thioredoxin reductase (TrxR) with an IC₅₀ of 4 μM.

HY-W013500

(1-Nitroethene-1,2-diyl)dibenzene alpha-Nitrostilbene; α-Nitrostilbene; NSC 385	Others	Others
(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) is an inhibitor of protein arginine methyltransferase 1 (PRMT1; IC₅₀=11 μM in histone H4 methylation assay). It also inhibits histone H4 methylation by PRMT8, but not histone H3.1 methylation by CARM1 or Set7/9, at concentrations of 10 and 100 μM.

HY-117583A

BG47	HDAC Histone Methyltransferase	Neurological Disease
BG47 is a prototypical histone deacetylases HDAC1 and HDAC2 selective, optoepigenetic probe. BG47 can bind to and competitively inhibits the deacetylase activity of HDAC targets upon a light-induced trans-to-cis isomerization, and increases Histone Methyltransferase H3K9 acetylation. BG47 can be used for neurological disease research .

HY-147230

EZH2-IN-13	Histone Methyltransferase	Cancer
EZH2-IN-13 is a potent EZH2 inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity .

HY-13808

UNC 0631 3 Publications Verification	Histone Methyltransferase	Cancer
UNC 0631 is a potent histone methyltransferase G9a inhibitor with an IC₅₀ of 4 nM. UNC 0631 potently reduces H3K9me2 levels in MDA-MB-231 cells with an IC₅₀ of 25 nM .

HY-15647

BRD9539 1 Publications Verification	Histone Methyltransferase	Cancer
BRD9539 is a histone methyltransferase G9a inhibitor with an IC₅₀ of 6.3 μM. BRD9539 also inhibits PRC2 activity and is inactive against SUV39H1, NSD2 and DNMT1 .

HY-10442

3-Deazaneplanocin A DZNep; 3-Deazaneplanocin	Histone Methyltransferase Orthopoxvirus	Infection Cancer
3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor . 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity .

HY-12310

RSC133	DNA Methyltransferase HDAC	Others
RSC133 exhibits dual activity by inhibiting histone deacetylase and DNA methyltransferase. RSC133 effectively facilitates reprogramming of human somatic cells to pluripotent stem cells and supports the maintenance of an undifferentiated state of human pluripotent stem cells .

HY-113786

EZH2-IN-21	Histone Methyltransferase	Cancer
EZH2-IN-21 is a potent inhibitor of the histone lysine methyltransferase enhancer of zeste homologue 2 (EZH2) with anticancer activity. EZH2-IN-21 is competitive with the cofactor SAM and noncompetitive with peptide or nucleosome substrates .

HY-164500

MC3629	Apoptosis Histone Methyltransferase	Cancer
MC3629 is an inhibitor of histone methyltransferase (EZH2) with anti-tumor activity. MC3629 inhibits SHH MB cancer cell proliferation and self-renewal and induces apoptosis. MC3629 can be used to study drug resistance in tumor aggressiveness .

HY-156455

SETD7-IN-1	Histone Methyltransferase	Cancer
SETD7-IN-1 (compound 7) is a PFI-2 (HY-18627) analogue. SETD7-IN-1 is a substrate and inhibitor of histone lysine methyltransferase SETD7, with an IC₅₀ of 0.96 ± 0.10 µM .

HY-116605

GSK926	Histone Methyltransferase	Cancer
GSK926 (compound 3) is a selective histone lysine methyltransferase EZH2 inhibitor (IC₅₀=0.02 μM; K_i=7.9 nM), with SAM-competitive and cell-active properties. GSK926 can be used in cancer research .

HY-12186

3-Deazaneplanocin A hydrochloride Maximum Cited Publications 26 Publications Verification DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Histone Methyltransferase Orthopoxvirus	Infection Cancer
3-Deazaneplanocin A hydrochloride (DZNep hydrochloride) is a potent histone methyltransferase EZH2 inhibitor . 3-Deazaneplanocin A hydrochlorideis a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor . 3-Deazaneplanocin A hydrochloride also has anti-orthopoxvirus and anti-variola activities .

HY-117583

cis-BG47	HDAC Histone Methyltransferase	Neurological Disease
cis-BG47 is an cis-isomer of BG47, BG47 is a prototypical histone deacetylases HDAC1 and HDAC2 selective, optoepigenetic probe. BG47 can bind to and competitively inhibits the deacetylase activity of HDAC targets upon a light-induced trans-to-cis isomerization, and increases Histone Methyltransferase H3K9 acetylation. cis-BG47 can be used for neurological disease research .

HY-P10570

[Nle20] H4 peptide (16−23)	Histone Methyltransferase	Cancer
[Nle20] H4 peptide (16−23) is a peptide with strong inhibitory activity against histone methyltransferase SETD8 (K_d=0.14 μM), which inhibits SETD8's methylation of histone H4 by competing with SETD8's substrate binding site. [Nle20] H4 peptide (16−23) can be used as a lead compound for anticancer therapy .

HY-135128

Dot1L-IN-5 1 Publications Verification	Histone Methyltransferase	Cancer
Dot1L-IN-5 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC₅₀ of 0.17 nM .

HY-135129

Dot1L-IN-6	Histone Methyltransferase	Cancer
Dot1L-IN-6 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC_{50 SPA DOT1L} of 0.19 nM .

HY-135127

Dot1L-IN-4	Histone Methyltransferase	Cancer
Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC_{50 SPA DOT1L} of 0.11 nM .

HY-153390

AMG-193	Histone Methyltransferase	Cancer
AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC₅₀=0.107 μM), thereby protecting normal cells with wild-type MTAP .

HY-160029

PRMT5-IN-32	Histone Methyltransferase	Cancer
PRMT5-IN-32 is an inhibitor of PRMT5. PRMT5-IN-32 inhibits HCT116 cell proliferation with an IC ₅₀ of 0.13 μM .

HY-116971

DCG066	Histone Methyltransferase Apoptosis	Cancer
DCG066 is an inhibitor of *lysine methyltransferase* G9a*. DCG066 can bind directly to G9a and inhibit methyltransferase* activity in vitro. DCG066 decreases di-methylation levels of histone H3 lysine 9 (H3K9Me2), inhibits cell proliferation and induces cell apoptosis. DCG066 displays low cytotoxicity in leukemia cell lines with high levels of G9a expression, including K562 .

HY-161670

NSD2-PWWP1 ligand 1	Histone Methyltransferase	Cancer
NSD2-PWWP1 ligand 1 (compound 34) is a small molecule ligand targeting the NSD2-PWWP1 domain (pIC50: 8.2). NSD2 is a large multidomain protein with histone writer and histone reader functions. Dysregulation of the levels of histone methyltransferase nuclear receptor binding SET domain 2 (NSD2) may lead to a variety of hematological and solid malignancies. NSD2-PWWP1 ligand 1 binds to NSD2, reducing its enzymatic activity and inhibiting tumorigenesis .

HY-12186G

3-Deazaneplanocin A hydrochloride DZNep hydrochloride; NSC 617989 hydrochloride; 3-Deazaneplanocin hydrochloride	Histone Methyltransferase Orthopoxvirus	Infection Cancer
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor .

HY-16705

BRD4770 3 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of *lysine 9 on histone* H3 (H3K9) with an EC₅₀** of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

HY-10930

UNC0321 2 Publications Verification	Histone Methyltransferase GCGR Apoptosis	Cancer
UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 63 pM and with assay-dependent IC₅₀ values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC₅₀ values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications .

HY-162003A

DCPT1061 hydrochloride	Histone Methyltransferase	Cancer
DCPT1061 hydrochloride has a strong inhibitory effect on PRMT1, PRMT6, and PRMT8 in vitro, The epigenetic enzymes such as PRMT3, PRMT4 and PRMT5 had little inhibitory effect. DCPT1061 hydrochloride has antitumor effects .

HY-149463

EZH2-IN-16	Histone Methyltransferase	Cancer
EZH2-IN-16 (Compound 24) is an inhibitor for histone methyltransferase (EZH2). EZH2-IN-16 inhibits EZH2 and EZH2 Y641F, with IC₅₀ of 37.6 and 79.1 nM. EZH2-IN-16 inhibits proliferation of WSU-DLCL2, with GI₅₀ of 0.2 μM .

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library

621 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 621 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L203

Methylation Compound Library

241 compounds

Methylation is an epigenetic modification mechanism that involves adding methyl groups to molecules such as DNA and histones, which can alter gene expression without changing the DNA sequence. This process is catalyzed by enzymes such as DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs), and can be reversed by demethylases. The balance of methylation and demethylation is crucial for maintaining cellular function and genomic stability. Abnormal regulation of methylation may lead to a variety of diseases, including cancer, neurological disorders, and developmental abnormalities. A deep understanding of the molecular mechanisms of methylation metabolism is essential for developing therapeutic strategies for diseases associated with methylation dysregulation.

MCE contains 241 compounds targeting methylation/demethylation enzymes, which is of significant value for studying the pathways of methylation metabolism and exploring their mechanisms of action in diseases.

HY-L005

Epigenetics Compound Library

1,263 compounds

Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.

MCE provide a unique collection of 1,263 epigenetics-related compounds that can be used in the research of the related diseases.

Cat. No.	Product Name	Type

HY-12186G

3-Deazaneplanocin A hydrochloride (GMP) DZNep hydrochloride (GMP); NSC 617989 hydrochloride (GMP); 3-Deazaneplanocin hydrochloride (GMP)	Fluorescent Dye
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor .

Cat. No.	Product Name	Type

HY-12186G

3-Deazaneplanocin A hydrochloride (GMP) DZNep hydrochloride (GMP); NSC 617989 hydrochloride (GMP); 3-Deazaneplanocin hydrochloride (GMP)	Biochemical Assay Reagents
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P2509

Histone H2A (1-20)	Peptides	Others
Histone H2A (1-20), a 35-residue a peptide of histone H2A, is a substrate for methyltransferase/demethylase enzymes .

HY-P2552

Histone H3 (1-21)	Peptides	Others
Histone H3 (1-21), derived from Histone H3 1-21 amino acids, is usually used as a substrate for methyltransferase (Histone 3 K4 and K9) and acetyltransferase (Histone 3 K9 and K14) assays .

HY-P2254

H3K27(Me3) (15-34)	Peptides	Cancer
H3K27(Me3) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-P2556

Histone H3 (21-44)	Peptides	Others
Histone H3 (21-44), derived from histone H3 21-44 amino acids, is usually used as a substrate (such as protein arginine methyltransferases) for methylation assays .

HY-P2554

Histone H3 (1-25), amide	Peptides	Others
Histone H3 (1-25), amide is an N-terminal peptide fragment of histone H3. Histone H3 (1-25), amide can be used to identify the substrate for histone methyltransferases (HMTs). Histone H3 (1-25), amide, as a substrate for HMT G9a, shows more efficient than histone H3 (15-39) and full-length histone H3 .

HY-P10570

[Nle20] H4 peptide (16−23)	Histone Methyltransferase	Cancer
[Nle20] H4 peptide (16−23) is a peptide with strong inhibitory activity against histone methyltransferase SETD8 (K_d=0.14 μM), which inhibits SETD8's methylation of histone H4 by competing with SETD8's substrate binding site. [Nle20] H4 peptide (16−23) can be used as a lead compound for anticancer therapy .

HY-P2252

H3K27(Me) (15-34)	Peptides	Cancer
H3K27(Me) (15-34), a histone peptide, is a repressive chromatin markderived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-P5922

PTD2 Ac-Gly-Val-Nle-Arg-Ile-NH2	Peptides	Cancer
PTD2 (Ac-Gly-Val-Nle-Arg-Ile-NH2) is a potent, selective inhibitor of WHSC1. PTD2 exhibits micromolar affinity towards WHSC1 .

HY-P10463

ssK36	Histone Methyltransferase	Cancer
ssK36 is a supersubstrate peptide of the histone methyltransferase (SET) domain protein 2 (SETD2), and ssK36 is designed for the SETD2 protein, a specific PKMT. It is responsible in human cells for adding methyl groups to the 36th lysine residue of histone H3 (H3K36) to form H3K36me3. ssK36 can be methylated by SETD2 at a rate more than 100 times faster than the natural substrate H3K36. ssK36 can be used to study the catalytic mechanism of PKMTs, especially substrate specificity and catalytic efficiency .

HY-P2253

H3K27(Me2) (15-34)	Peptides	Cancer
H3K27(Me2) (15-34), a histone peptide, is a repressive chromatin mark derived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-19554

MM-401	Histone Methyltransferase Apoptosis	Cancer
MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 μM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia .

Species:	Human (10)
Tag:	His (5) Tag Free (2) Myc (1) GST (3) Flag (1)
Source:	HEK293 (1) Sf9 insect cells (2) E. coli (7)

Cat. No.	Compare	Product Name	Species	Source

HY-P790095

	CARM1 Protein, Human (His) histone-arginine methyltransferase CARM1; Coactivator-associated arginine methyltransferase 1; Protein arginine N-methyltransferase 4; CARM1; PRMT4	Human	E. coli
	CARM1 Protein, Human (His) is the recombinant human-derived CARM1, expressed by E. coli , with C-10*His labeled tag. The total length of CARM1 Protein, Human (His) is 607 a.a.,

HY-P76080

	SMYD3 Protein, Human (sf9, GST) histone-lysine N-methyltransferase SMYD3; ZMYND1; ZNFN3A1	Human	Sf9 insect cells
	SMYD3 Protein, a histone methyltransferase, specifically induces di- and tri-methylation of H3K4, avoiding monomethylation, and methylates H4K5. Crucial in transcriptional activation within an RNA polymerase complex, SMYD3 also exhibits DNA-binding affinity for sequences containing 5'-CCCTCC-3' or 5'-GAGGGG-3'. SMYD3 Protein, Human (sf9, GST) is the recombinant human-derived SMYD3 protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of SMYD3 Protein, Human (sf9, GST) is 335 a.a., with molecular weight of ~58 kDa.

HY-P77218

	SUV420H2 Protein, Human (His) histone-lysine N-methyltransferase KMT5C; KMT5C; PP7130	Human	E. coli
	SUV420H2 protein is a histone methyltransferase that methylates H4K20 to generate H4K20me3 and H4K20me2, which are critical for transcriptional regulation and genome integrity. SUV420H2 functions in pericentric heterochromatin, establishes constitutive heterochromatin, and interacts with RB1 family proteins. SUV420H2 Protein, Human (His) is the recombinant human-derived SUV420H2 protein, expressed by E. coli , with N-His labeled tag.

HY-P76062

	SETD7 Protein, Human (His) histone-lysine N-methyltransferase SETD7; H3-K4-HMTase SETD7; SET7/9; KIAA1717; KMT7; SET7; SET9	Human	E. coli
	The SETD7 protein is a histone methyltransferase that specifically monomethylates H3K4, a mark associated with transcriptional activation. Its role in gene activation extends to the collagenase and insulin genes, specifically at the insulin promoter when IPF1/PDX-1 is recruited. SETD7 Protein, Human (His) is the recombinant human-derived SETD7 protein, expressed by E. coli , with N-His labeled tag. The total length of SETD7 Protein, Human (His) is 365 a.a., with molecular weight of 47-50 kDa.

HY-P700258

	Histone-lysine N-methyltransferase SMYD3(SMYD3) Protein, Human (His-Myc)	Human	E. coli
	SMYD3 Protein, a histone methyltransferase, specifically induces di- and tri-methylation of H3K4, avoiding monomethylation, and methylates H4K5. Crucial in transcriptional activation within an RNA polymerase complex, SMYD3 also exhibits DNA-binding affinity for sequences containing 5'-CCCTCC-3' or 5'-GAGGGG-3'. Histone-lysine N-methyltransferase SMYD3 (SMYD3) Protein, Human (His-Myc) is the recombinant human-derived Histone-lysine N-methyltransferase SMYD3(SMYD3) protein, expressed by E. coli , with N-10*His, C-Myc labeled tag. Histone-lysine N-methyltransferase SMYD3 (SMYD3) Protein, Human (His-Myc), has molecular weight of 56.5 kDa.

HY-P703071

	SETDB1 Protein, Human (sf9, GST) KMT1E; histone-lysine N-methyltransferase SETDB1; ERG-associated protein with SET domain (ESET); histone H3-K9 methyltransferase 4 (H3-K9-HMTase 4); Lysine N-methyltransferase 1E; SET domain bifurcated 1; SETDB1; ESET	Human	Sf9 insect cells
	SETDB1 Protein, Human (sf9, GST) is the recombinant human-derived SETDB1, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P76081

	SMYD3 Protein, Human (HEK293, His-Flag) histone-lysine N-methyltransferase SMYD3; ZMYND1; ZNFN3A1	Human	HEK293
	SMYD3 Protein, a histone methyltransferase, specifically induces di- and tri-methylation of H3K4, avoiding monomethylation, and methylates H4K5. Crucial in transcriptional activation within an RNA polymerase complex, SMYD3 also exhibits DNA-binding affinity for sequences containing 5'-CCCTCC-3' or 5'-GAGGGG-3'. SMYD3 Protein, Human (HEK293, His-Flag) is the recombinant human-derived SMYD3 protein, expressed by HEK293 , with C-His, C-Flag labeled tag.

HY-P701589

	KMT2D Protein, Human KMT2D; histone-lysine N-methyltransferase 2D; Lysine N-methyltransferase 2D; ALL1-related protein; Myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human is the recombinant human-derived KMT2D protein, expressed by E. coli , with tag free. The total length of KMT2D Protein, Human is 155 a.a., .

HY-P701590

	KMT2D Protein, Human (GST) KMT2D; histone-lysine N-methyltransferase 2D; Lysine N-methyltransferase 2D; ALL1-related protein; Myeloid/lymphoid or mixed-lineage leukemia protein 2	Human	E. coli
	KMT2D Protein, a histone methyltransferase, methylates histone H3 'Lys-4' (H3K4), predominantly establishing H3K4me1 marks at active chromatin sites. Integral to chromatin remodeling, it functions as a coactivator for the estrogen receptor, recruited by ESR1, activating transcription. KMT2D's role in depositing specific histone marks at genomic locations underscores its crucial involvement in modulating chromatin structure and gene expression. KMT2D Protein, Human (GST) is the recombinant human-derived KMT2D protein, expressed by E. coli , with N-GST labeled tag. The total length of KMT2D Protein, Human (GST) is 155 a.a., .

HY-P75283

	DOT1L Protein, Human histone H3-K79 methyltransferase; H3-K79-HMTase; DOT1L; KIAA1814; KMT4	Human	E. coli
	The DOT1L protein, a histone methyltransferase, methylates lysine-79 of histone H3. It shows high activity against nucleosomes but not free core histones. It is broadly expressed, particularly in tissues like the testis, bone marrow, and 22 other tissues. DOT1L Protein, Human is the recombinant human-derived DOT1L protein, expressed by E. coli , with tag free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83151

	SETD7 Antibody (YA2896) histone H3-K4 methyltransferase SETD7; Lysine N-methyltransferase 7; SET domain-containing protein 7; SET7; SET9	WB, IP	Human, Mouse, Rat
	SETD7 Antibody (YA2896) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2896), targeting SETD7, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). SETD7 Antibody (YA2896) can be used for WB, IP experiment in human, mouse, rat background.

HY-P81657

	KMT4 Antibody (YA1402) DOT 1; DOT1L; KMT4; histone methyltransferase DOT1L; H3 lysine-79 specific	WB, IHC-P	Human, Mouse
	KMT4 Antibody (YA1402) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1402), targeting KMT4, with a predicted molecular weight of 165 kDa (observed band size: 185 kDa). KMT4 Antibody (YA1402) can be used for WB, IHC-P experiment in human, mouse background.

HY-P83329

	NSD3 Antibody (YA3074) Wolf Hirschhorn syndrome candidate 1 like 1; WHSC1L1; NSD3; pp14328; histone-lysine N-methyltransferase NSD3; Protein whistle	WB, FC	Human, Mouse, Rat
	NSD3 Antibody (YA3074) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3074), targeting NSD3, with a predicted molecular weight of 162 kDa (observed band size: 162 kDa). NSD3 Antibody (YA3074) can be used for WB, FC experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

histone methyltransferase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products